A primer for measuring cGMP signaling and cGMP-mediated vascular relaxation

Adam C. Straub, Annie Beuve

Research output: Contribution to journalArticlepeer-review

Abstract

Soluble guanylyl cyclase (sGC, also called GC1) is the main receptor for nitric oxide (NO) that catalyzes the production of the second messenger molecule, 3′5′ cyclic guanosine monophosphate (cGMP) leading to vasorelaxation, and inhibition of leukocyte recruitment and platelet aggregation. Enhancing cGMP levels, through sGC agonism or inhibition of cGMP breakdown via phosphodiesterase inhibition, has yielded FDA approval for several cGMP modifier therapies for treatment of cardiovascular and pulmonary diseases. While basic research continues to improve our understanding of cGMP signaling and as new therapies evolve to elevate cGMP levels, we provide a short methodological primer for measuring cGMP and cGMP-mediated vascular relaxation for investigators.

Original languageEnglish (US)
Pages (from-to)40-45
Number of pages6
JournalNitric Oxide - Biology and Chemistry
Volume117
DOIs
StatePublished - Dec 1 2021

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Keywords

  • Catalytic activity
  • Guanylyl cyclase
  • Mesenteric arteries
  • Myography
  • Nitric oxide
  • VASP
  • cGMP

Fingerprint

Dive into the research topics of 'A primer for measuring cGMP signaling and cGMP-mediated vascular relaxation'. Together they form a unique fingerprint.

Cite this